A 5-year randomized trial on the safety and efficacy of pimecrolimus in atopic dermatitis: a critical appraisal – author response

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	1006
Number of pages	1
Journal	British Journal of Dermatology
Volume	177
Issue number	4
DOIs	https://doi.org/10.1111/bjd.15849
Publication status	Published - Oct 2017

Funding Information: Original study1 was funded by Novartis.

Access to Document

@article{02d5a8c0aa3c4c64a0e532361841f326,

title = "A 5-year randomized trial on the safety and efficacy of pimecrolimus in atopic dermatitis: a critical appraisal – author response",

author = "B. Sigurgeirsson and T. Luger",

note = "Funding Information: Original study1 was funded by Novartis.",

year = "2017",

month = oct,

doi = "10.1111/bjd.15849",

language = "English",

volume = "177",

pages = "1006",

journal = "British Journal of Dermatology",

issn = "0007-0963",

publisher = "Oxford University Press",

number = "4",

}

TY - JOUR

T1 - A 5-year randomized trial on the safety and efficacy of pimecrolimus in atopic dermatitis

T2 - a critical appraisal – author response

AU - Sigurgeirsson, B.

AU - Luger, T.

N1 - Funding Information: Original study1 was funded by Novartis.

PY - 2017/10

Y1 - 2017/10

UR - https://www.scopus.com/pages/publications/85030250082

U2 - 10.1111/bjd.15849

DO - 10.1111/bjd.15849

M3 - Article

C2 - 28940181

SN - 0007-0963

VL - 177

SP - 1006

JO - British Journal of Dermatology

JF - British Journal of Dermatology

IS - 4

ER -